Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, BidAskClub reports.
NBIX has been the subject of a number of other reports. Credit Suisse Group lowered Neurocrine Biosciences from an “outperform” rating to a “neutral” rating and set a $110.00 price target for the company. in a research note on Friday, December 13th. TheStreet raised Neurocrine Biosciences from a “c+” rating to a “b” rating in a research note on Tuesday, November 19th. Morgan Stanley increased their price target on Neurocrine Biosciences from $120.00 to $121.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Mizuho initiated coverage on Neurocrine Biosciences in a research note on Wednesday, February 5th. They set a “neutral” rating and a $107.00 price target for the company. Finally, Royal Bank of Canada reissued a “buy” rating and set a $125.00 price target on shares of Neurocrine Biosciences in a research note on Monday, January 20th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the company’s stock. Neurocrine Biosciences currently has a consensus rating of “Hold” and a consensus target price of $117.54.
Shares of Neurocrine Biosciences stock opened at $104.20 on Thursday. The stock has a 50 day moving average of $105.19 and a 200 day moving average of $102.75. Neurocrine Biosciences has a 12 month low of $71.85 and a 12 month high of $119.65. The firm has a market cap of $9.67 billion, a PE ratio of 315.76, a PEG ratio of 1.23 and a beta of 1.53. The company has a current ratio of 1.47, a quick ratio of 1.44 and a debt-to-equity ratio of 0.14.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, February 4th. The company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.40). Neurocrine Biosciences had a net margin of 4.70% and a return on equity of 8.27%. The firm had revenue of $244.10 million for the quarter, compared to the consensus estimate of $231.54 million. During the same period in the previous year, the company posted $0.19 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 85.8% on a year-over-year basis. As a group, equities research analysts forecast that Neurocrine Biosciences will post 3.52 earnings per share for the current fiscal year.
In other news, insider Eiry Roberts sold 2,632 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $111.11, for a total value of $292,441.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Malcolm Lloyd-Smith sold 28,969 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $104.56, for a total value of $3,028,998.64. Following the completion of the sale, the insider now directly owns 23,200 shares of the company’s stock, valued at $2,425,792. The disclosure for this sale can be found here. Insiders sold a total of 49,286 shares of company stock valued at $5,167,948 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.
Large investors have recently bought and sold shares of the company. Altshuler Shaham Ltd lifted its stake in shares of Neurocrine Biosciences by 172.9% in the 4th quarter. Altshuler Shaham Ltd now owns 262 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Evolution Wealth Advisors LLC raised its holdings in shares of Neurocrine Biosciences by 871.8% in the fourth quarter. Evolution Wealth Advisors LLC now owns 379 shares of the company’s stock worth $41,000 after buying an additional 340 shares during the period. Huntington National Bank raised its holdings in shares of Neurocrine Biosciences by 43,300.0% in the fourth quarter. Huntington National Bank now owns 434 shares of the company’s stock worth $47,000 after buying an additional 433 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter worth approximately $48,000. Finally, Robeco Institutional Asset Management B.V. purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter worth approximately $52,000. 95.30% of the stock is owned by institutional investors and hedge funds.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women’s health.
